GENE LOGIC Announces Collaboration with Johns Hopkins University for Schizophrenia and Depression Gene Discovery.

COLUMBIA, Md.--(BUSINESS WIRE)--April 1, 1997--GENE LOGIC INC. today announced the establishment of a research collaboration with Johns Hopkins University to discover genes associated with schizophrenia and depression. GENE LOGIC will use its proprietary Accelerated Target Discovery platform to identify new drug targets and drug leads for the development of novel pharmaceuticals and advanced diagnostics for schizophrenia and depression. The Johns Hopkins University collaboration is GENE LOGIC's second in the area of central nervous system gene discovery. Last week, GENE LOGIC announced its collaboration with Molecular Geriatrics Corporation for Alzheimer's disease gene discovery. Under the Johns Hopkins University collaboration, Dr. Robert Yolken, Professor of Pediatrics and Director of the Stanley Laboratory for the Study of Schizophrenia and Bipolar Disorder, will provide GENE LOGIC with access to an extensive, well-characterized library of brain tissue samples obtained postmortem from individuals diagnosed with schizophrenia, bipolar disorder or severe depression. These samples were collected as part of the Stanley Neuropathology program.

GENE LOGIC's Accelerated Target Discovery platform uses a proprietary system based on genomic technologies and bioinformatics to accelerate the discovery of novel drug targets. Using its READS(TM) technology, GENE LOGIC is able to produce a complete, quantitative picture of all the genes used in a human cell ("Molecular Topography(TM)"). Through its collaborations with Johns Hopkins, GENE LOGIC will create a "molecular movie," a series of Molecular Topographies(TM), showing the changes in gene expression patterns in the brain as schizophrenia and depression develop. These changes in gene expression will be analyzed using GENE LOGIC's GENE EXPRESS (TM) bioinformatics system to discover and prioritize potential drug targets. GENE LOGIC intends to license the drug targets and, potentially, drug lead compounds to pharmaceutical company partners for clinical development and commercialization.

GENE LOGIC INC., a privately-held company based in Columbia, MD, uses a proprietary system based on genomic technologies and bioinformatics to accelerate the discovery of novel drug targets. Such targets are critical to the development of innovative therapeutic products for major common diseases such as cancer, central nervous system disorders, osteoporosis and heart failure. To date, GENE LOGIC has raised $10 million from private investors, including Oxford Bioscience Partners and Hambro Health International.

CONTACT: GENE LOGIC INC.

Mark D. Gessler

SVP Corporate Development & CFO 

410/309-3100 x109

[e-mail]

www.genelogic.com

or

Burns McClellan, Inc.

James W. Heins, 212/505-1919

[e-mail]